Invention Publication
- Patent Title: REVERSAL BINDING AGENTS FOR ANTI-NATRIURETIC PEPTIDE RECEPTOR I (NPRI) ANTIBODIES AND USES THEREOF
-
Application No.: US18267403Application Date: 2021-12-13
-
Publication No.: US20240052042A1Publication Date: 2024-02-15
- Inventor: Yuichiro ADACHI , Jennifer R. ALLPORT-ANDERSON , Shaun R. COUGHLIN , John Louis DIENER , Lars GADTKE , Felix HARTLEPP , Tiancen HU , Alexander Wolfgang KOCH , Kathrin LADETZKI-BAEHS , Michael John ROMANOWSKI , Cesare RUSSO , Xenia Karola WEZLER , Xiaoling XIE
- Applicant: NOVARTIS AG
- Applicant Address: CH Basel
- Assignee: NOVARTIS AG
- Current Assignee: NOVARTIS AG
- Current Assignee Address: CH Basel
- International Application: PCT/IB2021/061664 2021.12.13
- Date entered country: 2023-06-14
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K45/06 ; A61P9/12
Abstract:
The present disclosure relates to use of reversal agents which specifically bind to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies or antigen binding fragments thereof, and reverse one or more effects of the anti-NPR1 antibody or antigen binding fragments thereof (e.g., hypotensive effects).
Information query
